← KAZIA THERAPEUTICS LTD (KZIA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
KAZIA THERAPEUTICS LTD (KZIA)
Pharmaceutical Preparations · market cap $160M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-06 (est.)
Earnings
Pipeline
6
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Kazia Therapeutics (KZIA) is a small-cap pharmaceutical company with 6 employees and a market cap of approximately $11.2 billion, trading near $12.98. Its lead asset is Paxalisib (GDC-0084), a Phase 2 candidate being evaluated in adult glioblastoma. No near-term catalysts are listed on the calendar and no recent catalysts have been disclosed.
The catalyst path
- 2026-11-06 (est.)Earningsimp 5/10
- 2026-12-01 (est.)Phase 2 · PAXALISIBimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Paxalisib (GDC-0084) | Phase 2 | Glioblastoma, Adult |
| Abemaciclib | Phase 2 | CDK Gene Mutation |
| Opdualag | Phase 2 | Childhood Cancer |
| PAXALISIB | Phase 2 | Primary Central Nervous System Lymphoma |
| Temozolomide capsule | Phase 2 | Malignant Primary Gliomas |
| Lomustine | Phase 3 | Glioblastoma |
Price & technical context
3-month
-28.5%
6-month
+27.4%
12-month
+36.5%
52-wk range
$5.00–$16.90
vs 50-day MA
-23.0%
vs 200-day MA
-10.7%
Realized vol
121.3%
Max drawdown
-90.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KZIA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.